What the Drug Supply Chain Security Act requires of pharmacies
The DSCSA builds an electronic, interoperable system to trace prescription drugs at the package level. For pharmacies — “dispensers” in the law — it sets rules on trading partners, tracing documentation, suspect and illegitimate products, and records.
The signal
The DSCSA, enacted in 2013 as Title II of the Drug Quality and Security Act, aims to identify and trace certain prescription drugs at the package level as they move through the U.S. supply chain — and pharmacies are part of that chain.
Why this matters
Pharmacies may trade only with authorized trading partners, must keep tracing documentation for the products they receive and must act quickly on suspect and illegitimate products. The package-level electronic requirements also change pharmacy systems and vendor relationships.
The 2-minute brief
The DSCSA was enacted in 2013 to build an interoperable, electronic way to trace prescription drugs at the package level, so harmful products can be kept out of the supply chain, detected and removed quickly.
For pharmacies that means buying only from authorized trading partners, accepting drugs only with product tracing documentation, keeping that documentation for six years, quarantining and investigating suspect products, and notifying FDA within 24 hours of determining that a product is illegitimate.
The enhanced requirements add secure electronic exchange and package-level verification. FDA has granted exemptions with later dates for small dispensers; its exemptions page lists the dates that currently apply.
What changed
- The DSCSA’s goals are to prevent harmful drugs from entering the U.S. drug supply chain, detect them if they do, and enable rapid response to remove them.[1]
- FDA advises pharmacies to check that manufacturers and repackagers are registered and that the wholesale distributors, third-party logistics providers and pharmacies they deal with are licensed.[2]
- Pharmacies must only accept prescription drugs accompanied by product tracing documentation, and must keep the documentation they receive for six years.[2]
- Pharmacies must have processes to quarantine and investigate suspect prescription drugs to determine whether they are illegitimate.[2]
- Trading partners, including dispensers, must notify FDA and appropriate immediate trading partners within 24 hours of determining that a product is illegitimate, using Form FDA 3911.[3]
- Under the enhanced drug distribution security requirements in section 582(g)(1), trading partners exchange transaction information securely and electronically and verify product at the package level, using a product identifier made up of the NDC and serial number, lot number and expiration date.[4]
- FDA has issued exemptions from certain section 582 requirements for small dispensers — those whose owning company has 25 or fewer full-time employees licensed as pharmacists or qualified as pharmacy technicians — and other trading partners may request waivers, exceptions or exemptions.[5]
Who this affects
- Pharmacies
- Pharmacists
- Pharmacy technicians
- Practice owners & operators
What to watch next
FDA’s DSCSA exemptions page, which lists the current compliance dates for small dispensers and other trading partners.[5]
Standards FDA publishes for the interoperable exchange of tracing information.[4]
NPHLA takeaway
For most pharmacies the practical work is in systems and contracts: confirm that trading partners are authorized, that tracing data arrives and can be retrieved for six years, and that there is a written process for suspect and illegitimate products. General information — confirm your obligations with counsel and your state board.
Source file
- [1]
- [2]
- [3]
- [4]
- [5]
- [6]
Drafted with AI assistance from the sources listed in the Source File, then reviewed and approved by an NPHLA editor before publication. NPHLA links to sources and does not republish their text. Professional information only — not medical, legal or regulatory advice for any individual situation. Our standards.